8 results
P
patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA)
I/C
coeliac disease (CD), biopsy-confirmed CD in RA and JIA patients
O
pooled prevalence estimates of biopsy-confirmed CD and positive CD serology
P
Patients with odontogenic keratocyst (OKC)
I/C
5-Fluorouracil (5-FU) as an adjunct following surgical intervention, Surgical intervention alone
O
Recurrence rate and nerve paraesthesia
P
MAC patients, AC patients
I/C
neoadjuvant treatment regimens comprising chemoradiotherapy (CRT) with fluorouracil (5-FU) or mFOLFOX6, neoadjuvant chemotherapy alone with mFOLFOX6 or mFOLFOXIRI, MAC vs. AC patients
O
pathological complete response (pCR) rate, tumor downstaging rate, 3-year DFS, 3-year locoregional recurrence rate
P
patients with locally advanced rectal cancer (LARC)
I/C
neoadjuvant (chemo) radiotherapy and curative surgery, observation group
O
overall survival (OS), disease-free survival (DFS), toxicity, compliance
P
chronic liver disease, hepatitis C, hepatitis B
I/C
antiviral therapy, hepatitis B, hepatitis C
O
health utility scores
P
5293
I/C
total glucosides of paeony, placebo, standard treatment
O
disease activity score (ASDAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-6, 28 joints disease activity (DAS28), psoriasis area and severity index (PASI), visual analogue scale (VAS), nitric oxide (NO)
P
patients with autoimmune disease and associated inflammatory ocular diseases
I/C
Janus kinase (JAK) inhibitors, . None of these 11 patients responded adequately to conventional treatments, including biological agents; these were all refractory cases and switched to JAK inhibitor therapy.
O
all 11 patients showed an improvement to JAK inhibitors without significant side effects
P
HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL)
I/C
DRUGS, SURGERY, PLACEBO
O
HISTOLOGICAL REGRESSION RATE OF CERVICAL LESIONS